search
Back to results

Combination Chemotherapy in Treating Patients With Colorectal Cancer

Primary Purpose

Colorectal Cancer

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
fluorouracil
irinotecan hydrochloride
leucovorin calcium
Sponsored by
Alliance for Clinical Trials in Oncology
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Colorectal Cancer focused on measuring stage III colon cancer, stage IV colon cancer, stage III rectal cancer, stage IV rectal cancer, recurrent colon cancer, recurrent rectal cancer, adenocarcinoma of the colon, adenocarcinoma of the rectum

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the colon or rectum Metastatic, locally advanced, or recurrent disease Patients must have at least 2 generations (parents and grandparents) who belong to one of the following racial groups: Asian or Pacific Islander (e.g., China, Japan, Korea, the Philippine Islands, or Samoa) Black (originating from the black racial groups of Africa) Hispanic (originating from Mexico, Puerto Rico, Cuba, Central or South America, or other Spanish culture) White (originating from the peoples of Europe, North Africa, or the Middle East) No patients with parents or grandparents of mixed race or race other than that of the patient PATIENT CHARACTERISTICS: Age: Not specified Performance status: CTC 0-2 Life expectancy: Not specified Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL AST no greater than 3 times upper limit of normal Renal: Creatinine no greater than 1.5 mg/dL Other: Not pregnant or nursing Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Prior adjuvant fluorouracil allowed if relapse occurred at least 6 months after completion of fluorouracil At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) No prior irinotecan No other concurrent chemotherapy Endocrine therapy: No concurrent hormones except steroids for adrenal failure, hormones for nondisease related conditions (e.g., insulin for diabetes), or intermittent dexamethasone as an antiemetic No concurrent prednisone Radiotherapy: At least 4 weeks since prior radiotherapy (except to bone or soft tissue involving less than 25% of bone marrow) No concurrent radiotherapy Surgery: At least 4 weeks since prior major surgery Other: No concurrent phenobarbital, valproate, or cyclosporine None of the following concurrently during first course of therapy: Macrolide antibiotics (e.g., azithromycin, erythromycin, clarithromycin, troleandomycin, dapsone) Azole antibiotics (e.g., fuconazole, miconazole, itraconazole, ketoconazole) Triazobenzodiazepines (e.g., alprazolam, midazolam, triazolam) Antidepressants (e.g., fluoxetine, setraline hydrochloride, fluoxamine, nefazodone hydrochloride) Quinolone antimicrobials (e.g., ciprofloxacin, ofloxacin) Imidazole antibiotics (e.g., clotrimazole) Anti-ulcer medications (e.g., omeprazole, lansoprazole) Ethinyl estradiol Diltiazem Cimetidine hydrochloride Cisapride Terfenadine Rifampin Glucocorticoids Antiepileptics Grapefruit juice

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    irinotecan + leucovorin + fluorouracil

    Arm Description

    Patients receive irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for a total of 5 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year and then every 6 months thereafter.

    Outcomes

    Primary Outcome Measures

    overall survival

    Secondary Outcome Measures

    Full Information

    First Posted
    August 3, 2000
    Last Updated
    July 1, 2016
    Sponsor
    Alliance for Clinical Trials in Oncology
    Collaborators
    National Cancer Institute (NCI)
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00006103
    Brief Title
    Combination Chemotherapy in Treating Patients With Colorectal Cancer
    Official Title
    Interracial Study of CPT-11 (Irinotecan) Pharmacokinetics in 5-Fluorouracil Refractory Colorectal Cancer: A Population Pharmacokinetic/Pharmacodynamic Study of CPT-11
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2016
    Overall Recruitment Status
    Completed
    Study Start Date
    July 2000 (undefined)
    Primary Completion Date
    April 2002 (Actual)
    Study Completion Date
    April 2002 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Alliance for Clinical Trials in Oncology
    Collaborators
    National Cancer Institute (NCI)

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if the effectiveness of irinotecan combined with fluorouracil in treating colorectal cancer varies depending on the patient's racial background. PURPOSE: Phase III trial to study the effectiveness of irinotecan combined with fluorouracil in treating patients from different racial backgrounds who have colorectal cancer that is advanced, recurrent, metastatic or has not responded to treatment with fluorouracil.
    Detailed Description
    OBJECTIVES: Determine the interracial differences in the pharmacokinetics of irinotecan in combination with fluorouracil in terms of SN-38 glucuronidation and biliary index, and gastrointestinal (GI) toxicity in patients with metastatic, locally advanced, or recurrent colorectal cancer. Determine if there is a significant relationship between UGT1A1 genotype (promoter and/or coding region mutation) and CYP3A4 promoter genotype, vs GI toxicity, bone marrow toxicity, and pharmacokinetics of irinotecan in this patient population. OUTLINE: Patients are stratified according to race (Asian or Pacific Islander vs black vs Hispanic vs white). Patients receive irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for a total of 5 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year and then every 6 months thereafter. PROJECTED ACCRUAL: A total of 400 patients (100 per stratum) will be accrued for this study within 3 years.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Colorectal Cancer
    Keywords
    stage III colon cancer, stage IV colon cancer, stage III rectal cancer, stage IV rectal cancer, recurrent colon cancer, recurrent rectal cancer, adenocarcinoma of the colon, adenocarcinoma of the rectum

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    400 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    irinotecan + leucovorin + fluorouracil
    Arm Type
    Experimental
    Arm Description
    Patients receive irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for a total of 5 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year and then every 6 months thereafter.
    Intervention Type
    Drug
    Intervention Name(s)
    fluorouracil
    Intervention Type
    Drug
    Intervention Name(s)
    irinotecan hydrochloride
    Intervention Type
    Drug
    Intervention Name(s)
    leucovorin calcium
    Primary Outcome Measure Information:
    Title
    overall survival
    Time Frame
    Up to 10 years

    10. Eligibility

    Sex
    All
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the colon or rectum Metastatic, locally advanced, or recurrent disease Patients must have at least 2 generations (parents and grandparents) who belong to one of the following racial groups: Asian or Pacific Islander (e.g., China, Japan, Korea, the Philippine Islands, or Samoa) Black (originating from the black racial groups of Africa) Hispanic (originating from Mexico, Puerto Rico, Cuba, Central or South America, or other Spanish culture) White (originating from the peoples of Europe, North Africa, or the Middle East) No patients with parents or grandparents of mixed race or race other than that of the patient PATIENT CHARACTERISTICS: Age: Not specified Performance status: CTC 0-2 Life expectancy: Not specified Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL AST no greater than 3 times upper limit of normal Renal: Creatinine no greater than 1.5 mg/dL Other: Not pregnant or nursing Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Prior adjuvant fluorouracil allowed if relapse occurred at least 6 months after completion of fluorouracil At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) No prior irinotecan No other concurrent chemotherapy Endocrine therapy: No concurrent hormones except steroids for adrenal failure, hormones for nondisease related conditions (e.g., insulin for diabetes), or intermittent dexamethasone as an antiemetic No concurrent prednisone Radiotherapy: At least 4 weeks since prior radiotherapy (except to bone or soft tissue involving less than 25% of bone marrow) No concurrent radiotherapy Surgery: At least 4 weeks since prior major surgery Other: No concurrent phenobarbital, valproate, or cyclosporine None of the following concurrently during first course of therapy: Macrolide antibiotics (e.g., azithromycin, erythromycin, clarithromycin, troleandomycin, dapsone) Azole antibiotics (e.g., fuconazole, miconazole, itraconazole, ketoconazole) Triazobenzodiazepines (e.g., alprazolam, midazolam, triazolam) Antidepressants (e.g., fluoxetine, setraline hydrochloride, fluoxamine, nefazodone hydrochloride) Quinolone antimicrobials (e.g., ciprofloxacin, ofloxacin) Imidazole antibiotics (e.g., clotrimazole) Anti-ulcer medications (e.g., omeprazole, lansoprazole) Ethinyl estradiol Diltiazem Cimetidine hydrochloride Cisapride Terfenadine Rifampin Glucocorticoids Antiepileptics Grapefruit juice
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Brian Leyland-Jones, MD
    Organizational Affiliation
    McGill Cancer Centre at McGill University
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Learn more about this trial

    Combination Chemotherapy in Treating Patients With Colorectal Cancer

    We'll reach out to this number within 24 hrs